CSL has announced on the
ASX that the US Food and Drug
Administration has accepted for
review CSL Behring’s Biologics
License Application (BLA)
for its novel investigational
recombinant factor VIII single-chain
(rVIIISingleChain) for the treatment
of haemophilia A.
The condition affects one in every
6,000 male births and this review
brings the only available treatment
one step closer to broader access,
said CSL’s Dr Andrew Cuthbertson.The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.